Skip to main content

Table 2 Median IC50 (microM) and IndexSUM values for single-agent gefitinib for all tumours tested.

From: The in vitroeffect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

Tumour

N

IC50 (microM)

IndexSUM

Breast adenocarcinoma

8

7.27 (6.2–16.9)

607 (500–785)

Colorectal adenocarcinoma

18

3.19 (0.1–52.6)

568 (239–818)

Melanoma – cutaneous (CMEL)

7

2.81 (1.9–29.4)

514 (471–587)

Melanoma – uveal (UMEL)

12

17.10 (0.04–69.9)

595 (187–746)

NSCLC

1

-

396

Squamous cell carcinoma

2

2.83 (2.3–3.4)

462 (454–469)

Oesophageal adenocarcinoma

4

3.58 (2.8–4.4)

602 (456–788)

Ovarian carcinoma

26

3.09 (0.2–23.1)

534 (269–777)

Carcinoma of unknown primary site (UPS)

5

4.76 (0.05–14.3)

612 (258–648)

Sarcoma

2

9.8

609 (588–630)

Sweat gland carcinoma

1

24.67

651

  1. (Negative values of IC50 have been excluded as meaningless. Negative values usually resulted from flat concentration – activity curve).